4D Molecular Therapeutics (FDMT) Change in Account Payables (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Change in Account Payables of $3.5 million for Q1 2026, up 1603.4% year-over-year from $207408.2 in Q1 2025, and down 17.76% quarter-over-quarter from $4.3 million in Q4 2025.
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) Change in Account Payables (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Change in Account Payables for 7 consecutive years, with $3.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 1603.4% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $10.5 million (up 15832.84% YoY), while the FY2025 annual figure was $6.8 million, up 677.61% from the prior year.
- Change in Account Payables slipped to $3.5 million in Q1 2026 per FDMT's latest filing, from $4.3 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $4.5 million in Q2 2025 and bottomed at -$1.8 million in Q3 2025.
- Historically, Change in Account Payables has averaged $613823.5 across 5 years, with a median of $226000.0 in 2022.
- Annual changes were most pronounced in 2022 — Change in Account Payables sank 313.46% — and 2026, when it jumped 1603.4%.
- 4D Molecular Therapeutics' Change in Account Payables stood at $1.5 million in 2022, then sank by 171.91% to -$1.1 million in 2023, then soared by 234.38% to $1.5 million in 2024, then soared by 193.84% to $4.3 million in 2025, then dropped by 17.76% to $3.5 million in 2026.
- Business Quant data shows FDMT's Change in Account Payables at $3.5 million in Q1 2026, $4.3 million in Q4 2025, and -$1.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - | -4.06 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.06 Mn |
| Mar 31, 2026 | 3.53 Mn |
| Dec 31, 2025 | 4.30 Mn |
| Sep 30, 2025 | -1.84 Mn |
| Jun 30, 2025 | 4.55 Mn |
| Mar 31, 2025 | -235,000.00 |
| Dec 31, 2024 | 1.46 Mn |
| Sep 30, 2024 | -508,000.00 |
| Jun 30, 2024 | -786,000.00 |
| Mar 31, 2024 | 703,000.00 |
| Dec 31, 2023 | -1.09 Mn |
| Sep 30, 2023 | 1.37 Mn |
| Jun 30, 2023 | 947,000.00 |
| Mar 31, 2023 | -333,000.00 |
| Dec 31, 2022 | 1.51 Mn |
| Sep 30, 2022 | -1.70 Mn |
| Jun 30, 2022 | 226,000.00 |
| Mar 31, 2022 | -1.68 Mn |
| Dec 31, 2021 | 1.66 Mn |
| Sep 30, 2021 | 795,000.00 |